Aug. 4 at 5:05 AM
$VERU The Financial Times profiled Novo CEO Mike Doustdar’s effort to make Novo more aggressive following its recent setbacks. The article says he remains open to large acquisitions while seeking growth in obesity, cardiovascular, liver, kidney and other areas. Doustdar also signalled he would consider far bigger deals than Pfizer’s
$10BN acquisition of obesity drug developer Metsera after a takeover battle with Novo, saying that was not a “large” transaction in his eyes. Speaking before news broke of talks between AstraZeneca and Bristol Myers Squibb over a potential
$400BN pharma mega-merger, he said: “Probably today we are in more data rooms than ever before looking into anything and everything that is out there.” But he stressed that the company prioritised assets that fill gaps in its portfolio over size.
